RISK STRATIFICATION FOR PATIENTS WITH FIRST LOCAL RECURRENCE OF RETROPERITONEAL LIPOSARCOMA (FLORRAL)

TARPSWG, SSO 2024, Atlanta

David Gyorki Eyal Mor












Background

- Previous TARPSWG study (Chan wt al Clin Cancer Res 2019)
- 684 patients from 22 TARPSWG centres, 2002-2011
- Included all histologies
- Most recurrences after resection of first LR are local and outcome is determined by histologic subtype






Background

- Predictors of LR after second resection for RPS

Table 3. Multivariable analysis

| Factor | DFS After second surgery | | OS After second surgery | |
|--|--------------------------|---------|-------------------------|---------|
| | HR (95% CI) | P | HR (95% CI) | P |
| Resected number of organs at first surgery | 1.31 (1.04-1.63) | 0.001 | 1.57 (1.17-2.11) | 0.002 |
| Age at second surgery | _ | _ | 1.33 (1.10-1.59) | 0.005 |
| Multifocality at second surgery, yes vs. no | 1.87 (1.54-2.27) | < 0.001 | 1.78 (1.39-2.28) | < 0.001 |
| Grade - 3 vs. 1-2 | 1.51 (1.21-1.87) | < 0.001 | 1.82 (1.37-2.40) | < 0.001 |
| Completeness of surgery at second surgery, incomplete vs. complete | 1.65 (1.27-2.15) | < 0.001 | 2.14 (1.55-2.96) | < 0.001 |
| Histology | | 0.013 | | 0.001 |
| LMS vs. DDLPS | 1.14 (0.85-1.54) | | 0.79 (0.54-1.15) | |
| WDLPS vs. DDLPS | 0.66 (0.51-0.85) | | 0.46 (0.32-0.66) | |
| MPNST vs. DDLPS | 1.53 (0.62-3.77) | | 1.21 (0.37-3.98) | |
| Other vs. DDLPS | 1.11 (0.82-1.50) | | 1.02 (0.70-1.49) | |
| SFT vs. DDLPS | 0.94 (0.54-1.66) | | 0.51 (0.24-1.11) | |
| Chemotherapy administered at first surgery, yes vs. no | 1.22 (0.93-1.61) | 0.145 | _ | _ |
| Radiotherapy administered at first surgery, yes vs. no | 1.06 (0.80-1.41) | 0.679 | 1.15 (0.82-1.62) | 0.407 |

Background







ORIGINAL ARTICLE - BONE AND SOFT TISSUE SARCOMAS

Management of Recurrent Retroperitoneal Sarcoma (RPS) in the Adult: A Consensus Approach from the Trans-Atlantic RPS Working Group

Trans-Atlantic RPS Working Group

- 8. Abdominal (nonhepatic parenchymal) recurrence should be categorized as
- (a) locoregional (at the site of the primary RPS or within the ipsilateral RP);
- (b) multifocal/contralateral RP;
- (c) both (VB).



FLORRAL



Study design

• Retrospective multicentre study

Hypothesis

- Outcome following resection of first local recurrence of retroperitoneal liposarcoma differs based on the location of the recurrence and
- the location of recurrence impacts decision making regarding management of recurrence

Primary objective

• To identify novel risk factors to predict recurrence risk following curative intent treatment of first local recurrence of retroperitoneal liposarcoma

Secondary objective

- To describe the pattern of 2nd recurrence of retroperitoneal liposarcomas
- To identify predictors of early local relapse after surgical resection of first local recurrence



Eligibility criteria

• Patients who have undergone curative intent surgical resection of first local recurrence of retroperitoneal liposarcoma – surgery for recurrence must be at TARPWSG site (primary resection can be at outside centre)

Data points of interest


- Primary resection size, grade, site, extent of resection, high vs low vol centre, neoadj chemo/RT
- Recurrence Site*, size, rate of growth, solitary vs multifocal, neoadj chemo/RT

Secondary objective

- To describe the pattern of 2nd recurrence of retroperitoneal liposarcomas
- To identify predictors of early local relapse after surgical resection of first local recurrence



Site of recurrence



Data points of interest

- Patients demographics Age, sex, ECOG.
- <u>Data from the primary surgery</u>: Date of diagnosis, Date of surgery, Referral centre vs community centre.
- Operative strategy for primary tumour Limited resection vs planned multivisceral resection
- Organs resected en-bloc with primary sarcoma.
- Preop RT Y/N (dose/fractions)
- Preop chemo Y/N (regimen)
- Size of primary
- Grade of primary
- Subtype of primary.
- Side of primary Right/left/pelvic
- Post-operative management -
- Post-operative complications Total number of complications,
 Major complication (classified as Clavien Dindo of 3 and more),
 re-operation rate and reasons.
- Adjuvant treatment (type, reason)
- Pattern of first recurrence based on imaging:
- Site of recurrence (based of illustration on figure 1)
- Multifocal recurrence (Y/N)



- Date recurrence first detected (date of CT)
- Date of most recent CT
- Size of recurrence.
- Management of first local recurrence
 - Neoadjuvant RT
 - Neoadjuvant chemo
 - Extent of surgery
 - Postoperative complications
- Pathology of first local recurrence
 - Size, grade etc
- Recurrent presentation and management:
- Futher recurrence Y/N
- Treatment for 2nd recurrence yes/no/unknown
- Surgery for 2nd recurrence yes/no/unknown
- Reason for no surgery
- Date of surgery for recurrence
- Type of surgery for recurrence
- Chemo/radiation for recurrence.
- Date of last follow up
- Status at last follow up

Logistics



- Opt in
- Data sharing with Petermac through RESAR data sharing platform although participating sites not currently recruiting to RESAR welcome to contribute (will need separate DTA with Petermac)
- This study will hopefully inform the interpretation of results from ReLAPSe study (PI Angela Hong)
- Questions

david.gyorki@petermac.org







